|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8-9
|
|
pubmed:dateCreated |
2009-9-8
|
|
pubmed:abstractText |
Taxane-based adjuvant chemotherapy is the current standard for node-positive breast cancer patients. Recent data identified relevant patient subgroups with questionable benefit. To estimate the incremental burden on health care resources and costs, we compared a modern sequential regimen (4x epirubicin/cyclophosphamide; 4x docetaxel: EC-->DOC) to CMF.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1423-0240
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
473-81
|
|
pubmed:meshHeading |
pubmed-meshheading:19736510-Anthracyclines,
pubmed-meshheading:19736510-Antineoplastic Agents,
pubmed-meshheading:19736510-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19736510-Breast Neoplasms,
pubmed-meshheading:19736510-Chemotherapy, Adjuvant,
pubmed-meshheading:19736510-Cisplatin,
pubmed-meshheading:19736510-Female,
pubmed-meshheading:19736510-Fluorouracil,
pubmed-meshheading:19736510-Germany,
pubmed-meshheading:19736510-Health Care Costs,
pubmed-meshheading:19736510-Humans,
pubmed-meshheading:19736510-Male,
pubmed-meshheading:19736510-Methotrexate,
pubmed-meshheading:19736510-Middle Aged,
pubmed-meshheading:19736510-Prevalence,
pubmed-meshheading:19736510-Taxoids,
pubmed-meshheading:19736510-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
|
|
pubmed:affiliation |
Dept. of Gynecology, Klinikum rechts der Isar der Technischen Universität München (TUM), Germany.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
